comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 16:24:48 - browse：554

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： KalVista pill reduced swelling 'attacks' caused by genetic disease

focus

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Texas Medical Board asked to define abortion emergency exception

How digital tools helped lower hypertension in marginalized patients

What’s missing from the debate over nursing home staff minimums

Senators start work on Medicare physician payment reform

entertainment

comprehensive

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

'Revelatory' study finds a smoking impact that remains after quitting

Hepatitis C has a cure — but many Americans still lack access to it

'Revelatory' study finds a smoking impact that remains after quitting

How to save PrEP access — and even expand it

Adopting new red light myopia treatments may be short

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Amgen, Regeneron, BGI Group and more

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Amgen, Regeneron, BGI Group and more

entertainment

Readout LOUD podcast: How biotech is using artificial intelligence

Medicare Advantage plans can’t deny care with AI, CMS warns

Medicare Advantage plans can’t deny care with AI, CMS warns

Why Novartis is going to walk from its acquisition of MorphoSys

To avoid data mishandling cases, universities eye AI and other tools

Texas Medical Board asked to define abortion emergency exception

focus

leisure time

entertainment

knowledge